| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1034018829 |
| P356 | DOI | 10.1007/S11912-015-0494-5 |
| P698 | PubMed publication ID | 26769114 |
| P2093 | author name string | Ali A Mokdad | |
| Amit G Singal | |||
| Adam C Yopp | |||
| P2860 | cites work | Hepatic artery embolization in 32 patients with unresectable hepatoma | Q72648254 |
| Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma | Q80595806 | ||
| Phase I targeted combination trial of sorafenib and erlotinib in patients with advanced solid tumors | Q80798279 | ||
| Consideration of role of radiotherapy for lymph node metastases in patients with HCC: retrospective analysis for prognostic factors from 125 patients | Q81781138 | ||
| EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization | Q84441129 | ||
| Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma | Q24235977 | ||
| EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma | Q27860783 | ||
| New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada | Q27860904 | ||
| Sorafenib in advanced hepatocellular carcinoma | Q27861075 | ||
| Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma | Q28247867 | ||
| Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial | Q29547903 | ||
| Hepatocellular carcinoma | Q29616359 | ||
| Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival | Q29616865 | ||
| Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver | Q29616866 | ||
| BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis | Q29617585 | ||
| Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial | Q29617955 | ||
| Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma | Q29617957 | ||
| Prognosis of hepatocellular carcinoma: the BCLC staging classification | Q29619984 | ||
| Reporting results of cancer treatment | Q29620070 | ||
| A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. | Q33368982 | ||
| Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study | Q33384665 | ||
| Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial | Q33410643 | ||
| Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial | Q33423800 | ||
| Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study | Q33631372 | ||
| Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma: a two-cohort study | Q33691454 | ||
| Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma. | Q33918062 | ||
| Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials | Q34068152 | ||
| Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma | Q34246444 | ||
| Systemic therapy for hepatocellular carcinoma | Q34422663 | ||
| Chemoembolization for hepatocellular carcinoma | Q34552214 | ||
| Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer | Q34560933 | ||
| Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06). | Q34617414 | ||
| Survival analysis of patients with stage I and II hepatocellular carcinoma after a liver transplantation or liver resection | Q34618740 | ||
| Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization. | Q34622672 | ||
| Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design. | Q34635723 | ||
| Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial | Q34663499 | ||
| Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. | Q34714683 | ||
| A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma | Q34721838 | ||
| Radiotherapy for osseous metastases from hepatocellular carcinoma: a retrospective study of 57 patients | Q34754880 | ||
| Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial | Q34786090 | ||
| Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes | Q35004090 | ||
| Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma | Q35085486 | ||
| Hong Kong consensus recommendations on the management of hepatocellular carcinoma | Q35631295 | ||
| The Global Burden of Cancer 2013 | Q35847426 | ||
| Transarterial chemoembolization plus sorafenib: a sequential therapeutic scheme for HCV-related intermediate-stage hepatocellular carcinoma: a randomized clinical trial. | Q35863880 | ||
| Resection and liver transplantation for hepatocellular carcinoma. | Q36140302 | ||
| Yttrium 90 radioembolization for the treatment of hepatocellular carcinoma: biological lessons, current challenges, and clinical perspectives | Q37068157 | ||
| Modified RECIST (mRECIST) assessment for hepatocellular carcinoma | Q37696396 | ||
| Current strategy for staging and treatment: the BCLC update and future prospects. | Q37696399 | ||
| Which response criteria best help predict survival of patients with hepatocellular carcinoma following chemoembolization? A validation study of old and new models | Q37970349 | ||
| Use of Lipiodol as a drug-delivery system for transcatheter arterial chemoembolization of hepatocellular carcinoma: a review | Q38127071 | ||
| Hepatocellular carcinoma: reasons for phase III failure and novel perspectives on trial design | Q38192888 | ||
| Cost effectiveness of radioembolization compared with conventional transarterial chemoembolization for treatment of hepatocellular carcinoma | Q38214883 | ||
| Treatment of intermediate-stage hepatocellular carcinoma | Q38236876 | ||
| Early hepatocellular carcinoma on the procrustean bed of ablation, resection, and transplantation. | Q38264956 | ||
| Transarterial chemoembolization: modalities, indication, and patient selection | Q38355409 | ||
| Advances in targeted therapies for hepatocellular carcinoma in the genomic era. | Q38521011 | ||
| Treatment of Liver Tumors with Lipiodol TACE: Technical Recommendations from Experts Opinion. | Q38590448 | ||
| Adherence to American Association for the Study of Liver Diseases guidelines for the management of hepatocellular carcinoma: results of an Italian field practice multicenter study | Q39466409 | ||
| Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models | Q40198053 | ||
| Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial | Q40548309 | ||
| Establishment of a multidisciplinary hepatocellular carcinoma clinic is associated with improved clinical outcome | Q41690819 | ||
| Phase 2 trial of linifanib (ABT-869) in patients with unresectable or metastatic hepatocellular carcinoma | Q43607983 | ||
| Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study | Q43691230 | ||
| Comparison of the methods for tumor response assessment in patients with hepatocellular carcinoma undergoing transarterial chemoembolization | Q43872109 | ||
| A snapshot of the effective indications and results of surgery for hepatocellular carcinoma in tertiary referral centers: is it adherent to the EASL/AASLD recommendations?: an observational study of the HCC East-West study group | Q44983320 | ||
| The ART-strategy: sequential assessment of the ART score predicts outcome of patients with hepatocellular carcinoma re-treated with TACE. | Q45346670 | ||
| Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. | Q45980006 | ||
| Adherence to AASLD guidelines for the treatment of hepatocellular carcinoma in clinical practice: experience of the Bologna Liver Oncology Group. | Q46391590 | ||
| Review article: Overview of medical treatments in unresectable hepatocellular carcinoma--an impossible meta-analysis? | Q47734769 | ||
| The combination of transcatheter arterial chemoembolization and sorafenib is well tolerated and effective in Asian patients with hepatocellular carcinoma: final results of the START trial | Q48238287 | ||
| SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma. | Q50454368 | ||
| Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. | Q50535030 | ||
| Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. | Q51082254 | ||
| Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. | Q51642133 | ||
| Applicability of BCLC stage for prognostic stratification in comparison with other staging systems: single centre experience from long-term clinical outcomes of 1717 treatment-naïve patients with hepatocellular carcinoma. | Q53379427 | ||
| Treatment variables related to liver toxicity in patients with hepatocellular carcinoma, Child-Pugh class A and B enrolled in a phase 1-2 trial of stereotactic body radiation therapy. | Q53534881 | ||
| Yttrium-90 radioembolization vs sorafenib for intermediate-locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis | Q56970979 | ||
| Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma | Q57214428 | ||
| Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: A phase 2 study | Q57763422 | ||
| Sequential Phase I and II Trials of Stereotactic Body Radiotherapy for Locally Advanced Hepatocellular Carcinoma | Q59678030 | ||
| P433 | issue | 2 | |
| P304 | page(s) | 9 | |
| P577 | publication date | 2016-02-01 | |
| P1433 | published in | Current Oncology Reports | Q2264969 |
| P1476 | title | Advances in Local and Systemic Therapies for Hepatocellular Cancer | |
| P478 | volume | 18 |
| Q89931742 | Hsa_circ_0003645 shows an oncogenic role by sponging microRNA-1299 in hepatocellular carcinoma cells |
| Q60924931 | Inhibition of autophagy enhances adenosine‑induced apoptosis in human hepatoblastoma HepG2 cells |
| Q91756549 | Intensive Care Unit Admission and Survival in Stage IV Cancer Patients with Septic Shock: A Population-Based Cohort Study |
| Q46742830 | Micelle-enhanced direct spectrofluorimetric method for the determination of linifanib: Application to stability studies |
| Q92291497 | Temperature mapping of exothermic in situ chemistry: imaging of thermoembolization via MR |
Search more.